NCT04704271 (THC-Gender-II) is a Phase 1 clinical trial of Inhaled THC in Cannabis, sponsored by Yale University.

Who is sponsoring NCT04704271?

NCT04704271 is sponsored by Yale University.

What drugs are being tested in NCT04704271?

Interventions in NCT04704271: Inhaled THC, Placebo.

Is NCT04704271 still recruiting?

NCT04704271 is currently recruiting now. Last updated 6 March 2025.

Last reviewed 2025-03-06 · How we verify

NCT04704271: THC-Gender-II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II

Recruiting now Phase 1 Last updated 6 March 2025

What this trial tests

Phase 1 trial testing Inhaled THC in Cannabis in 100 participants. Currently enrolling.

Timeline

9 October 2019

Primary endpoint
1 December 2025

1 December 2025

Quick facts

Lead sponsor	Yale University
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	basic science
Enrollment	100
Start date	9 October 2019
Primary completion	1 December 2025
Estimated completion	1 December 2025
Sites	1 location across United States

Drugs / interventions tested

Inhaled THC — full drug profile →
Placebo

Conditions studied

Cannabis — all drugs for Cannabis →

Sponsor

Yale University

Who can join

Adults 18 to 55, any sex, with Cannabis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cannabis

Currently open trials in the same condition.

NCT05999383 — Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration · Phase 2 · recruiting
NCT07417059 — Sex Hormones Impact on Cannabis Response · NA · recruiting
NCT07194018 — Use of Cannabis Oil in Fibromyalgia · active not recruiting
NCT06099379 — Modulation of THC Effects by CBD: a Dose-ranging Study · Phase 1, PHASE2 · recruiting
NCT05742724 — The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol · Phase 1 · active not recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04704271 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 6 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04704271.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing